Gazyva combined with chemotherapy failed to meet its primary endpoints in a Phase III trial for patients with previously untreated diffuse large B-cell lymphoma.
According to Derek Lowe, writing in his “In The Pipeline” blog for Science Translational Medicine on July 15, AstraZeneca has announced job cuts at its MedImmune division. The gist of the rumors was confirmed by a Friday, July 15 statement released by the company.
The China Food and Drug Administration has approved GSK’s human papillomavirus vaccine Cervarix for use in the country to help women fight cervical cancer.
AstraZeneca Plc said its experimental lung cancer drug Tagrisso met its main goal in a late-stage study.
Biosimilars maker Samsung Bioepis, part of South Korea’s top family-run conglomerate Samsung Group, said it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc.’s rheumatoid arthritis drug Humira.
Herbalife Ltd. agreed to a $200 million settlement with U.S. regulators under which the dietary supplements maker will change the way it does business and avoid being labeled a pyramid scheme, a blow to hedge fund manager Bill Ackman who for years has been betting against the company.
Valeant’s experimental drug to treat psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, according to an FDA preliminary review.
Martin Shkreli will finally have his day in court. The disgraced former pharmaceutical entrepreneur will face a judge in June 2017, Reuters reported.
Juno Therapeutics has indicated that instead of three patient fatalities out of 129 cases for the company’s Phase II clinical trial of JCAR015 for relapsed or refractory B cell acute lymphoblastic leukemia, there were actually four.